抄録
The therapeutic effect of combination chemotherapy on 49 non-Hodgkin's lymphoma patients aged 70 or older who had been treated at the National Cancer Center Hospital over 24 years was analyzed on the basis of their response rates, duration of remission, and survival from treatment. The group [ADM (+)], treated with regimens including adriamycin, was compared with the group [ADM (-)] treated with regimens excluding adriamycin.
There were no statistically significant imbalances between these two groups with respect to age, sex, primary site, clinical stage or histologic subtype.
Complete response was seen in 10 out of 21 patients (46.4%) and in 11 out of 28 patients (39.3%) for the ADM (+) group and the ADM (-) group, respectively. The period of complete remission of the ADM (+) and ADM (-) groups was compared using the log-rank method. The duration of the former was significantly (p<0.05) loner than that of the latter and the median duration of remission was 20 months and 4 months, respectively. The median survival time from treatment was 22 months for the ADM (+) group and 14 months for the ADM (-) group, but no significant difference was observed between the two groups.
Therapy-related mortality or serious complications were not observed in both groups.
